Josep Brugada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5106595/publications.pdf

Version: 2024-02-01

554 papers 53,407 citations

100 h-index 217 g-index

602 all docs 602 docs citations

times ranked

602

21121 citing authors

#	Article	IF	CITATIONS
1	Accuracy of standard bipolar amplitude voltage thresholds to identify late potential channels in ventricular tachycardia ablation. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 15-25.	1.3	5
2	Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study. Europace, 2022, 24, 774-783.	1.7	5
3	Clinical impact of rare variants associated with inherited channelopathies: a 5-year update. Human Genetics, 2022, 141, 1579-1589.	3.8	11
4	The prevalence of left and right bundle branch block morphology ventricular tachycardia amongst patients with arrhythmogenic cardiomyopathy and sustained ventricular tachycardia: insights from the European Survey on Arrhythmogenic Cardiomyopathy. Europace, 2022, 24, 285-295.	1.7	7
5	Late gadolinium enhancementâ€MRI determines definite lesion formation most accurately at 3 months post ablation compared to later time points. PACE - Pacing and Clinical Electrophysiology, 2022, 45, 72-82.	1.2	10
6	Clinical Genetics of Inherited Arrhythmogenic Disease in the Pediatric Population. Biomedicines, 2022, 10, 106.	3.2	9
7	Paediatric and adolescent athletes in Switzerland: age-adapted proposals for pre-participation cardiovascular evaluation. Swiss Medical Weekly, 2022, 152, w30128.	1.6	3
8	Discerning the Ambiguous Role of Missense TTN Variants in Inherited Arrhythmogenic Syndromes. Journal of Personalized Medicine, 2022, 12, 241.	2.5	2
9	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. Nature Genetics, 2022, 54, 232-239.	21.4	55
10	<i>BAG3</i> Genetic Cardiomyopathy May Overlap Fulminant Myocarditis Clinical Findings. Circulation: Heart Failure, 2022, 15, e008443.	3.9	1
11	Brugada Syndrome in Women: What Do We Know After 30 Years?. Frontiers in Cardiovascular Medicine, 2022, 9, 874992.	2.4	5
12	Late Potential Abolition in Ventricular Tachycardia Ablation. American Journal of Cardiology, 2022, 174, 53-60.	1.6	6
13	Análisis clÃnico e histopatológico de la prevalencia de enfermedades cardiacas en muerte súbita. Estudio en autopsias. Repertorio De Medicina Y Cirugia, 2022, 31, 161-169.	0.1	O
14	Brugada Syndrome. Methodist DeBakey Cardiovascular Journal, 2021, 10, 25.	1.0	110
15	Atrial fibrillation ablation after the CABANA study: beyond statistical dogma. Revista Espanola De Cardiologia (English Ed), 2021, 74, 129-130.	0.6	O
16	Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. Europace, 2021, 23, 49-58.	1.7	6
17	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57
18	Malignant Arrhythmogenic Role Associated with RBM20: A Comprehensive Interpretation Focused on a Personalized Approach. Journal of Personalized Medicine, 2021, 11, 130.	2.5	4

#	Article	IF	CITATIONS
19	Optimized singleâ€point left ventricular pacing leads to improved resynchronization compared with multipoint pacing. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 519-527.	1.2	2
20	Update on the Diagnostic Pitfalls of Autopsy and Post-Mortem Genetic Testing in Cardiomyopathies. International Journal of Molecular Sciences, 2021, 22, 4124.	4.1	17
21	Ablation of a life-threatening arrhythmia in a patient with Brugada syndrome. Global Cardiology Science & Practice, 2021, 2021, e202104.	0.4	1
22	The year in cardiovascular medicine 2020: arrhythmias. Cardiologia Croatica, 2021, 16, 107-116.	0.0	3
23	Analysis of Brugada syndrome loci reveals that fine-mapping clustered GWAS hits enhances the annotation of disease-relevant variants. Cell Reports Medicine, 2021, 2, 100250.	6.5	4
24	Long-term prognosis of women with Brugada syndrome and electrophysiological study. Heart Rhythm, 2021, 18, 664-671.	0.7	13
25	Proximity to the descending aorta predicts regional fibrosis in the adjacent left atrial wall: aetiopathogenic and prognostic implications. Europace, 2021, 23, 1559-1567.	1.7	9
26	Cardiac magnetic resonance to predict recurrences after ventricular tachycardia ablation: septal involvement, transmural channels, and left ventricular mass. Europace, 2021, 23, 1437-1445.	1.7	12
27	Reply to the Editorâ€"Electrophysiologic study in women with Brugada Syndrome. Heart Rhythm, 2021, 18, 1039-1040.	0.7	0
28	Right ventricular function and dyssynchrony in Brugada syndrome: Highlighting the importance of the mechanical substrate in the right ventricular outflow tract. International Journal of Cardiology, 2021, 333, 233-238.	1.7	5
29	Early Identification of Prolonged QT Interval for Prevention of Sudden Infant Death. Frontiers in Pediatrics, 2021, 9, 704580.	1.9	3
30	Ablation in Brugada Syndrome: A Review of Two Cases. Current Problems in Cardiology, 2021, , 100937.	2.4	0
31	Genotype-Phenotype Correlation of <i>SCN5A</i> Genotype in Patients With Brugada Syndrome and Arrhythmic Events: Insights From the SABRUS in 392 Probands. Circulation Genomic and Precision Medicine, 2021, 14, e003222.	3.6	7
32	Nonâ€invasive isthmus identification of complex arrhythmias in congenital heart disease. Journal of Arrhythmia, 2021, 37, 1562-1566.	1.2	0
33	Validation of multiparametric approaches for the prediction of sudden cardiac death in patients with Brugada syndrome and electrophysiological study. Revista Espanola De Cardiologia (English Ed), 2021,	0.6	1
34	The year in cardiovascular medicine 2020: arrhythmias. European Heart Journal, 2021, 42, 499-507.	2.2	4
35	Sport practice in hypertrophic cardiomyopathy: running to stand still?. International Journal of Cardiology, 2021, 345, 77-82.	1.7	12
36	Implantable Loop Recorders in Brugada syndrome: an ally?. Heart Rhythm, 2021, , .	0.7	0

#	Article	lF	CITATIONS
37	Characterization of electrocardiographic findings in young students. Revista Espanola De Cardiologia (English Ed), 2020, 73, 139-144.	0.6	3
38	In-hospital and 12-month follow-up outcome from the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry: sex differences. Europace, 2020, 22, 66-73.	1.7	33
39	2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 655-720.	2.2	647
40	The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope. American Heart Journal, 2020, 220, 213-223.	2.7	15
41	Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators. Diabetes Care, 2020, 43, 196-200.	8.6	11
42	Paediatric arrhythmology: a challenge of the 21st century. Anales De PediatrÃa (English Edition), 2020, 92, 1-2.	0.2	1
43	Cryoballoon vs. radiofrequency lesions as detected by late-enhancement cardiac magnetic resonance after ablation of paroxysmal atrial fibrillation: a case–control study. Europace, 2020, 22, 382-387.	1.7	11
44	Ablation strategies for different types of atrial fibrillation in Europe: results of the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry. Europace, 2020, 22, 558-566.	1.7	11
45	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. Europace, 2020, 22, 250-258.	1.7	7
46	Update on Genetic Basis of Brugada Syndrome: Monogenic, Polygenic or Oligogenic?. International Journal of Molecular Sciences, 2020, 21, 7155.	4.1	36
47	Magnetic resonance-guided re-ablation for atrial fibrillation is associated with a lower recurrence rate: a case–control study. Europace, 2020, 22, 1805-1811.	1.7	18
48	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. Circulation, 2020, 142, 324-338.	1.6	83
49	Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. European Heart Journal, 2020, 41, 3437-3447.	2.2	78
50	The arrhythmogenic right ventricular cardiomyopathy in comparison to the athletic heart. Journal of Cardiovascular Electrophysiology, 2020, 31, 1836-1843.	1.7	16
51	Genetic Variants as Sudden-Death Risk Markers in Inherited Arrhythmogenic Syndromes: Personalized Genetic Interpretation. Journal of Clinical Medicine, 2020, 9, 1866.	2.4	5
52	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. PLoS Medicine, 2020, 17, e1003040.	8.4	20
53	Electromechanical delay by speckle-tracking echocardiography: A novel tool to distinguish between Brugada syndrome and isolated right bundle branch block. International Journal of Cardiology, 2020, 320, 161-167.	1.7	3
54	Sex-specific efficacy and safety of cryoballoon versus radiofrequency ablation for atrial fibrillation: An individual patient data meta-analysis. Heart Rhythm, 2020, 17, 1232-1240.	0.7	11

#	Article	IF	Citations
55	Ventricular scar channel entrances identified by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac defibrillators. Europace, 2020, 22, 598-606.	1.7	28
56	Very high pacing thresholds during longâ€ŧerm followâ€up predicted by a combination of implant pacing threshold and impedance in leadless transcatheter pacemakers. Journal of Cardiovascular Electrophysiology, 2020, 31, 868-874.	1.7	20
57	Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617.	2.2	15
58	Sudden Cardiac Death and Copy Number Variants: What Do We Know after 10 Years of Genetic Analysis?. Forensic Science International: Genetics, 2020, 47, 102281.	3.1	20
59	Reanalysis and reclassification of rare genetic variants associated with inherited arrhythmogenic syndromes. EBioMedicine, 2020, 54, 102732.	6.1	46
60	Pediatric Malignant Arrhythmias Caused by Rare Homozygous Genetic Variants in TRDN: A Comprehensive Interpretation. Frontiers in Pediatrics, 2020, 8, 601708.	1.9	3
61	Differential Diagnosis of Wide QRS Tachycardias. Arrhythmia and Electrophysiology Review, 2020, 9, 155-160.	2.4	11
62	Brugada Syndrome. , 2020, , 231-246.		0
63	Brugada syndrome, Brugada phenocopy, or simply arrythmia induced by cocaine intoxication?. Emergencias, 2020, 32, 72-74.	0.6	0
64	Short QT Syndrome: A Comprehensive Genetic Interpretation and Clinical Translation of Rare Variants. Journal of Clinical Medicine, 2019, 8, 1035.	2.4	33
65	QRS Variations During Arrhythmias. Cardiac Electrophysiology Clinics, 2019, 11, 315-331.	1.7	1
66	Influence of risk factors in the ESCâ€EHRA EORP atrial fibrillation ablation longâ€term registry. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1365-1373.	1.2	15
67	Electrocardiogram in Newborns: Beneficial or Not?. Pediatric Cardiology, 2019, 40, 1320-1321.	1.3	2
68	Ethnic differences in patients with Brugada syndrome and arrhythmic events: New insights from Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2019, 16, 1468-1474.	0.7	22
69	Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. Europace, 2019, 21, 1802-1808.	1.7	11
70	Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. Lancet, The, 2019, 394, 1344-1351.	13.7	49
71	Out-of-hospital cardiac arrest due to idiopathic ventricular fibrillation in patients with normal electrocardiograms: results from a multicentre long-term registry. Europace, 2019, 21, 1670-1677.	1.7	34
72	Optimizing Cardiac Resynchronization Therapy Devices in Follow-up to Improve Response Rates and Outcomes. Cardiac Electrophysiology Clinics, 2019, 11, 89-98.	1.7	2

#	Article	IF	CITATIONS
73	Personalized Interpretation and Clinical Translation of Genetic Variants Associated With Cardiomyopathies. Frontiers in Genetics, 2019, 10, 450.	2.3	6
74	Long-term outcome of neonates and infants with permanent junctional reciprocating tachycardia. When cardiac ablation changes natural history. Journal of Electrocardiology, 2019, 56, 85-89.	0.9	8
75	Management of anticoagulation in patients undergoing leadless pacemaker implantation. Heart Rhythm, 2019, 16, 1849-1854.	0.7	12
76	Repeat Ablation for Atrial Fibrillation Recurrence Post Cryoballoon or Radiofrequency Ablation in the FIRE AND ICE Trial. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007247.	4.8	116
77	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. European Journal of Heart Failure, 2019, 21, 690-693.	7.1	3
78	Genetic interpretation and clinical translation of minor genes related to Brugada syndrome. Human Mutation, 2019, 40, 749-764.	2.5	32
79	Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome. Journal of the American College of Cardiology, 2019, 73, 1756-1765.	2.8	53
80	Digenic Heterozigosity in SCN5A and CACNA1C Explains the Variable Expressivity of the Long QT Phenotype in a Spanish Family. Revista Espanola De Cardiologia (English Ed), 2019, 72, 324-332.	0.6	4
81	Failure-free survival of the Riata implantable cardioverter-defibrillator lead after a very long-term follow-up. Indian Pacing and Electrophysiology Journal, 2019, 19, 140-144.	0.6	1
82	Brugada Syndrome: anesthetic considerations and management algorithm. Minerva Anestesiologica, 2019, 85, 173-188.	1.0	10
83	Time-to-first appropriate shock in patients implanted prophylactically with an implantable cardioverter-defibrillator: data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Europace, 2019, 21, 796-802.	1.7	16
84	Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESCâ€EHRA Atrial Fibrillation Ablation Longâ€Term Registry. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 313-320.	1.2	9
85	Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry. Europace, 2019, 21, 581-589.	1.7	69
86	Rationale and design of the EU ERTâ€ŀCD prospective study: comparative effectiveness of prophylactic ICD implantation. ESC Heart Failure, 2019, 6, 182-193.	3.1	18
87	Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart, 2019, 105, 244-250.	2.9	67
88	Clinical classification of rare cardiac arrhythmogenic and conduction disorders, and rare arrhythmias. Polish Archives of Internal Medicine, 2019, 129, 154-159.	0.4	4
89	Role of copy number variants in sudden cardiac death and related diseases: genetic analysis and translation into clinical practice. European Journal of Human Genetics, 2018, 26, 1014-1025.	2.8	26
90	General Anesthesia Attenuates Brugada Syndrome Phenotype Expression. JACC: Clinical Electrophysiology, 2018, 4, 518-530.	3.2	23

#	Article	IF	Citations
91	Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design. Clinical Research in Cardiology, 2018, 107, 539-547.	3.3	12
92	Assessing the Malignant Ventricular Arrhythmic Substrate in Patients With Brugada Syndrome. Journal of the American College of Cardiology, 2018, 71, 1631-1646.	2.8	68
93	Fever-related arrhythmic events in the multicenter Survey on Arrhythmic Events in Brugada Syndrome. Heart Rhythm, 2018, 15, 1394-1401.	0.7	71
94	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace, 2018, 20, e1-e160.	1.7	767
95	Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 117-124.	1.3	3
96	Improvement of Reverse RemodelingÂUsing Electrocardiogram Fusion-Optimized Intervals in CardiacÂResynchronization Therapy. JACC: Clinical Electrophysiology, 2018, 4, 181-189.	3.2	64
97	Cardiopulmonary resuscitation and use of the automatic external defibrillator in sport. Apunts Medicine De L'Esport, 2018, 53, 29-31.	0.5	0
98	Profile of patients with Brugada syndrome presenting with their first documented arrhythmic event: Data from the Survey on Arrhythmic Events in BRUgada Syndrome (SABRUS). Heart Rhythm, 2018, 15, 716-724.	0.7	57
99	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace, 2018, 20, 157-208.	1.7	375
100	Clinical outcome of patients with the Brugada type 1 electrocardiogram without prophylactic implantable cardioverter defibrillator in primary prevention: a cumulative analysis of seven large prospective studies. Europace, 2018, 20, f77-f85.	1.7	23
101	The longâ€QT syndrome and exercise practice: The neverâ€ending debate. Journal of Cardiovascular Electrophysiology, 2018, 29, 489-496.	1.7	22
102	Postprocedural LGEâ€CMR comparison of laser and radiofrequency ablation lesions after pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1065-1072.	1.7	15
103	Impact of Female Sex on Clinical Outcomes in the FIRE AND ICE Trial of Catheter Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006204.	4.8	78
104	Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. Journal of the American College of Cardiology, 2018, 71, 1325-1333.	2.8	14
105	Impact of left atrial volume, sphericity, and fibrosis on the outcome of catheter ablation for atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2018, 29, 740-746.	1.7	30
106	Antitachycardia Pacing Effectiveness for Monomorphic Ventricular Tachycardia in Brugada Syndrome After Quinidine Administration. Revista Espanola De Cardiologia (English Ed), 2018, 71, 403-406.	0.6	0
107	The Girona Territori Cardioprotegit Project: Performance Evaluation of Public Defibrillators. Revista Espanola De Cardiologia (English Ed), 2018, 71, 79-85.	0.6	5
108	Pulmonary function predicts mortality and hospitalizations in outpatients with heart failure and preserved ejection fraction. Respiratory Medicine, 2018, 134, 124-129.	2.9	9

#	Article	IF	Citations
109	Recent Advances in Short QT Syndrome. Frontiers in Cardiovascular Medicine, 2018, 5, 149.	2.4	60
110	The FIRE AND ICE Trial: What We Know, What We Can Still Learn, and What We Need to Address in the Future. Journal of the American Heart Association, 2018, 7, e010777.	3.7	17
111	Delayed Gadolinium Enhancement Magnetic Resonance Imaging Detected Anatomic Gap Length in Wide Circumferential Pulmonary Vein Ablation Lesions Is Associated With Recurrence of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006659.	4.8	28
112	Integration of "Omics―Strategies for Biomarkers Discovery and for the Elucidation of Molecular Mechanisms Underlying Brugada Syndrome. Proteomics - Clinical Applications, 2018, 12, e1800065.	1.6	6
113	Molecular autopsy in a cohort of infants died suddenly at rest. Forensic Science International: Genetics, 2018, 37, 54-63.	3.1	10
114	Present Status of Brugada Syndrome. Journal of the American College of Cardiology, 2018, 72, 1046-1059.	2.8	291
115	Preferential regional distribution of atrial fibrosis in posterior wall around left inferior pulmonary vein as identified by late gadolinium enhancement cardiac magnetic resonance in patients with atrial fibrillation. Europace, 2018, 20, 1959-1965.	1.7	47
116	Gender differences in patients with Brugada syndrome and arrhythmic events: Data from a survey on arrhythmic events in 678 patients. Heart Rhythm, 2018, 15, 1457-1465.	0.7	65
117	Primary electrical disorders and arrhythmogenic right ventricular cardiomyopathy: new research insights with clinical implications. Europace, 2018, 20, f1-f2.	1.7	0
118	Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. Journal of the American Heart Association, 2018, 7, .	3.7	20
119	Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 913-923.	9.1	45
120	Electrocardiographic Assessment and Genetic Analysis in Neonates: a Current Topic of Discussion. Current Cardiology Reviews, 2018, 15, 30-37.	1.5	5
121	Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. European Heart Journal, 2017, 38, ehw526.	2.2	83
122	Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. European Heart Journal, 2017, 38, ehw506.	2.2	22
123	Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. European Heart Journal, 2017, 38, ehw564.	2.2	151
124	Genetic analysis in post-mortem samples with micro-ischemic alterations. Forensic Science International, 2017, 271, 120-125.	2.2	1
125	Sudden Arrhythmic Death During Exercise: A Post-Mortem Genetic Analysis. Sports Medicine, 2017, 47, 2101-2115.	6.5	11
126	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm, 2017, 14, e275-e444.	0.7	1,671

#	Article	IF	Citations
127	Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2017, 10, e005053.	4.8	177
128	Brugada Syndrome and Exercise Practice: Current Knowledge, Shortcomings and Open Questions. International Journal of Sports Medicine, 2017, 38, 573-581.	1.7	16
129	Short QT syndrome in pediatrics. Clinical Research in Cardiology, 2017, 106, 393-400.	3.3	18
130	Left atrial fibrosis quantification by late gadolinium-enhanced magnetic resonance: a new method to standardize the thresholds for reproducibility. Europace, 2017, 19, 1272-1279.	1.7	103
131	A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia. Forensic Science International, 2017, 270, 173-177.	2.2	2
132	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Journal of Arrhythmia, 2017, 33, 369-409.	1.2	348
133	Ventricular Arrhythmias in the Absence of Structural Heart Disease. Cardiovascular Medicine, 2017, , 205-217.	0.0	0
134	Patients With Brugada Syndrome and Implanted Cardioverter-Defibrillators. Journal of the American College of Cardiology, 2017, 70, 1991-2002.	2.8	34
135	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Journal of Interventional Cardiac Electrophysiology, 2017, 50, 1-55.	1.3	83
136	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Heart Rhythm, 2017, 14, e445-e494.	0.7	135
137	Ventricular Arrhythmias Ablation in Brugada Syndrome. Current and Future Directions. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1046-1049.	0.6	3
138	The Impact of Cryoballoon Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation on Healthcare Utilization and Costs: An Economic Analysis From the FIRE AND ICE Trial. Journal of the American Heart Association, 2017, 6, .	3.7	38
139	Intermittent alternance of Brugada ECG patterns: Insights from a unique electrophysiological phenomenon. Journal of Cardiovascular Electrophysiology, 2017, 28, 1482-1484.	1.7	0
140	Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respiratory Medicine, the, 2017, 5, 935-945.	10.7	235
141	Atrial fibrillation ablation. Unsolved questions, many possible answers. Revista Portuguesa De Cardiologia, 2017, 36, 7-8.	0.5	1
142	Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. International Journal of Cardiology, 2017, 244, 229-234.	1.7	113
143	Prevention of sudden death in adolescent athletes: Incremental diagnostic value and cost-effectiveness of diagnostic tests. European Journal of Preventive Cardiology, 2017, 24, 1446-1454.	1.8	29
144	Characterizing the spectrum of right ventricular remodelling in response to chronic training. International Journal of Cardiovascular Imaging, 2017, 33, 331-339.	1.5	13

#	Article	IF	Citations
145	Effect of cardiac resynchronization therapy in patients with diabetes randomized in <pre><scp>EchoCRT</scp></pre> . European Journal of Heart Failure, 2017, 19, 80-87.	7.1	5
146	Medico-legal perspectives on sudden cardiac death in young athletes. International Journal of Legal Medicine, 2017, 131, 393-409.	2.2	21
147	Age of First Arrhythmic Event in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	57
148	Cardiac Channelopathies and Sudden Death: Recent Clinical and Genetic Advances. Biology, 2017, 6, 7.	2.8	88
149	Large Genomic Imbalances in Brugada Syndrome. PLoS ONE, 2016, 11, e0163514.	2.5	23
150	Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. European Heart Journal, 2016, 37, 2858-2865.	2.2	272
151	Spatiotemporal Characteristics of QRS Complexes Enable the Diagnosis of Brugada Syndrome Regardless of the Appearance of a Type 1 ECG. Journal of Cardiovascular Electrophysiology, 2016, 27, 563-570.	1.7	4
152	Left Atrial Geometry Improves Risk Prediction of Thromboembolic Events in Patients With Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2016, 27, 804-810.	1.7	38
153	Association of cardiac resynchronization therapy with the incidence of appropriate implantable cardiac defibrillator therapies in ischaemic and non-ischaemic cardiomyopathy. Europace, 2016, 19, euw303.	1.7	2
154	Muerte súbita en el deportista. Medicina ClÃnica, 2016, 147, 540-542.	0.6	4
155	Sudden death in the athlete. Medicina ClÃnica (English Edition), 2016, 147, 540-542.	0.2	0
156	Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. New England Journal of Medicine, 2016, 374, 2235-2245.	27.0	1,423
157	Status of cardiac resynchronization therapy in Catalonia, Spain: Results of the prospective multicentric study TRC-CAT. Medicina ClÂnica (English Edition), 2016, 146, 423-428.	0.2	1
158	Long-Term Trends in Newly Diagnosed Brugada Syndrome. Journal of the American College of Cardiology, 2016, 68, 614-623.	2.8	72
159	Genetic basis of dilated cardiomyopathy. International Journal of Cardiology, 2016, 224, 461-472.	1.7	67
160	Exerciseâ€Induced Brugada Phenocopy. Journal of Cardiovascular Electrophysiology, 2016, 27, 360-361.	1.7	4
161	Effect of Gender on Outcomes After Cardiac Resynchronization Therapy in Patients With a Narrow QRS Complex. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	19
162	Epicardial mapping and ablation of the right ventricle substrate during flecainide testing in Brugada syndrome. HeartRhythm Case Reports, 2016, 2, 52-56.	0.4	2

#	Article	IF	Citations
163	Dyssynchronization reduces dynamic obstruction without affecting systolic function in patients with hypertrophic obstructive cardiomyopathy: a pilot study. International Journal of Cardiovascular Imaging, 2016, 32, 1179-1188.	1.5	7
164	Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy. Europace, 2016, 18, 232-237.	1.7	12
165	Regional differences in referral, procedures, and outcome after ablation for atrial fibrillation in Europe: a report from the Atrial Fibrillation Ablation Pilot Registry of the European Society of Cardiology. Europace, 2016, 18, 191-200.	1.7	13
166	Differentiating hypertrophic cardiomyopathy from athlete's heart: An electrocardiographic and echocardiographic approach. Journal of Electrocardiology, 2016, 49, 539-544.	0.9	12
167	Sudden infant death syndrome caused by cardiac arrhythmias: only a matter of genes encoding ion channels?. International Journal of Legal Medicine, 2016, 130, 415-420.	2.2	28
168	Gene-Specific Therapy for Congenital Long QT Syndrome. Journal of the American College of Cardiology, 2016, 67, 1059-1061.	2.8	6
169	Disabling Palpitations in an Adolescent. JAMA Cardiology, 2016, 1, 107.	6.1	0
170	Sudden death in structurally normal heart: we have learned a lot, but still a long way to go. European Heart Journal, 2016, 37, 638-639.	2.2	3
171	Expert cardiologists cannot distinguish between Brugada phenocopy and Brugada syndrome electrocardiogram patterns. Europace, 2016, 18, 1095-1100.	1.7	57
172	Monomorphic ventricular tachycardia in patients with Brugada syndrome: A multicenter retrospective study. Heart Rhythm, 2016, 13, 669-682.	0.7	67
173	Emerging risk factors and the dose–response relationship between physical activity and lone atrial fibrillation: a prospective case–control study. Europace, 2016, 18, 57-63.	1.7	115
174	Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. European Heart Journal, 2016, 37, 49-59.	2.2	43
175	Contact force threshold for permanent lesion formation in atrial fibrillation ablation: A cardiac magnetic resonance–based study to detect ablation gaps. Heart Rhythm, 2016, 13, 37-45.	0.7	29
176	Infarct transmurality as a criterion for first-line endo-epicardial substrate–guided ventricular tachycardia ablation in ischemic cardiomyopathy. Heart Rhythm, 2016, 13, 85-95.	0.7	68
177	Brugada syndrome: clinical and genetic findings. Genetics in Medicine, 2016, 18, 3-12.	2.4	102
178	Natural and Undetermined Sudden Death: Value of Post-Mortem Genetic Investigation. PLoS ONE, 2016, 11, e0167358.	2.5	62
179	Brugada Syndrome. , 2016, , 175-191.		0
180	Genetics of channelopathies associated with sudden cardiac death. Global Cardiology Science & Practice, 2015, 2015, 39.	0.4	29

#	Article	IF	CITATIONS
181	Prognosis of newâ€onset heart failure outpatients and collagen biomarkers. European Journal of Clinical Investigation, 2015, 45, 842-849.	3.4	19
182	Genetics of inherited arrhythmias in pediatrics. Current Opinion in Pediatrics, 2015, 27, 665-674.	2.0	10
183	Genetic Analysis of Arrhythmogenic Diseases in the Era of NGS: The Complexity of Clinical Decision-Making in Brugada Syndrome. PLoS ONE, 2015, 10, e0133037.	2.5	46
184	Comprehensive Genetic Characterization of a Spanish Brugada Syndrome Cohort. PLoS ONE, 2015, 10, e0132888.	2.5	25
185	Base of the triangle to determine a Brugada electrocardiogram pattern. Europace, 2015, 17, 505-505.	1.7	4
186	Robust detection of ECG waves. , 2015, , .		0
187	3D delayed-enhanced magnetic resonance sequences improve conducting channel delineation prior to ventricular tachycardia ablation. Europace, 2015, 17, 938-945.	1.7	110
188	Left atrial deformation predicts success of first and second percutaneous atrial fibrillation ablation. Heart Rhythm, 2015, 12, 11-18.	0.7	70
189	Ventricular Fibrillation Inducibility in the Early Repolarization Syndrome. Journal of the American College of Cardiology, 2015, 65, 160-162.	2.8	2
190	Effect of Study Design on the Reported Effect of Cardiac Resynchronization Therapy (CRT) on Quantitative Physiological Measures: Stratified Metaâ€Analysis in Narrowâ€QRS Heart Failure and Implications for Planning Future Studies. Journal of the American Heart Association, 2015, 4, e000896.	3.7	10
191	An easy-to-use, operator-independent, clinical model to predict the left vs. right ventricular outflow tract origin of ventricular arrhythmias. Europace, 2015, 17, 1122-1128.	1.7	16
192	The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. European Heart Journal, 2015, 36, 1983-1989.	2.2	65
193	Scar Dechanneling. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 326-336.	4.8	200
194	Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2015, 12, 1636-1643.	0.7	38
195	Optimized pacing mode for hypertrophic cardiomyopathy: Impact of ECG fusion during pacing. Heart Rhythm, 2015, 12, 909-916.	0.7	9
196	Impact of earliest activation site location in the septal right ventricular outflow tract for identification of left vs right outflow tract origin of idiopathic ventricular arrhythmias. Heart Rhythm, 2015, 12, 726-734.	0.7	25
197	Ablation of frequent PVC in patients meeting criteria for primary prevention ICD implant: Safety of withholding the implant. Heart Rhythm, 2015, 12, 2434-2442.	0.7	40
198	Short QT and atrial fibrillation: A KCNQ1 mutation–specific disease. Late follow-up in three unrelated children. HeartRhythm Case Reports, 2015, 1, 193-197.	0.4	12

#	Article	IF	Citations
199	Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1373-1381.	4.8	210
200	A Novel Mutation in Lamin A/C Causing Familial Dilated Cardiomyopathy Associated With Sudden Cardiac Death. Journal of Cardiac Failure, 2015, 21, 217-225.	1.7	24
201	Usefulness of antitachycardia pacing in arrhythmogenic right ventricular dysplasia/cardiomyopathy. International Journal of Cardiology, 2015, 181, 172-173.	1.7	1
202	Genetic analysis, in silico prediction, and family segregation in long QT syndrome. European Journal of Human Genetics, 2015, 23, 79-85.	2.8	16
203	Quantification of local changes in myocardial motion by diffeomorphic registration via currents: Application to paced hypertrophic obstructive cardiomyopathy in 2D echocardiographic sequences. Medical Image Analysis, 2015, 19, 203-219.	11.6	5
204	Clinical interpretation of genetic variants in arrhythmogenic right ventricular cardiomyopathy. Clinical Research in Cardiology, 2015, 104, 288-303.	3.3	13
205	Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. European Heart Journal, 2015, 36, 425-433.	2.2	291
206	Stop-Gain Mutations in PKP2 Are Associated with a Later Age of Onset of Arrhythmogenic Right Ventricular Cardiomyopathy. PLoS ONE, 2014, 9, e100560.	2.5	22
207	ldentification of Genetic Alterations, as Causative Genetic Defects in Long QT Syndrome, Using Next Generation Sequencing Technology. PLoS ONE, 2014, 9, e114894.	2.5	26
208	Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). European Heart Journal, 2014, 35, 501-507.	2.2	285
209	Reversal of spherical remodelling of the left atrium after pulmonary vein isolation: incidence and predictors. Europace, 2014, 16, 840-847.	1.7	23
210	Usefulness of contrast-enhanced cardiac magnetic resonance in identifying the ventricular arrhythmia substrate and the approach needed for ablation. European Heart Journal, 2014, 35, 1316-1326.	2.2	114
211	New electrocardiographic criteria to differentiate the Type-2 Brugada pattern from electrocardiogram of healthy athletes with r'-wave in leads V1/V2. Europace, 2014, 16, 1639-1645.	1.7	68
212	Post-mortem genetic analysis in juvenile cases of sudden cardiac death. Forensic Science International, 2014, 245, 30-37.	2.2	44
213	<scp>EAARN</scp> score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on preâ€implantation risk factors. European Journal of Heart Failure, 2014, 16, 802-809.	7.1	59
214	Longâ€term effectiveness of the combined minute ventilation and patient activity sensors as predictor of heart failure events in patients treated with cardiac resynchronization therapy: Results of the Clinical Evaluation of the Physiological Diagnosis Function in the ⟨scp⟩PARADYM CRT⟨ scp⟩ device Trial (⟨scp⟩CLEPSYDRA⟨ scp⟩) study. European Journal of Heart Failure, 2014, 16, 663-670.	7.1	25
215	Rationale and study design of the <scp>NEuroCardiac TherApy foR</scp> Heart Failure Study: <scp>NECTARâ€HF</scp> . European Journal of Heart Failure, 2014, 16, 692-699.	7.1	56
216	Fusionâ€Optimized Intervals (FOI): A New Method to Achieve the Narrowest QRS for Optimization of the AV and VV Intervals in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2014, 25, 283-292.	1.7	58

#	Article	IF	CITATIONS
217	Letter by Berruezo et al Regarding Article, "Impact of Local Ablation on Interconnected Channels Within Ventricular Scar: Mechanistic Implications for Substrate Modification― Circulation: Arrhythmia and Electrophysiology, 2014, 7, 362-362.	4.8	O
218	Benefit of Left Atrial Roof Linear Ablation in Paroxysmal Atrial Fibrillation: A Prospective, Randomized Study. Journal of the American Heart Association, 2014, 3, e000877.	3.7	37
219	Automatic Optimization of Cardiac Resynchronization Therapy Using SonR—Rationale and Design of the Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the Paradym RF SonR CRT-D (RESPOND CRT) Trial. American Heart Journal, 2014, 167, 429-436.	2.7	26
220	Usefulness of Echocardiography in Preparticipation Screening of Competitive Athletes. Revista Espanola De Cardiologia (English Ed), 2014, 67, 701-705.	0.6	20
221	CMR-Guided Approach to Localize and Ablate Gaps in Repeat AF Ablation Procedure. JACC: Cardiovascular Imaging, 2014, 7, 653-663.	5.3	129
222	Cardiac Rhythm Management Devices. Journal of the American College of Cardiology, 2014, 63, 1776-1777.	2.8	0
223	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 29-47.	1.2	16
224	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Journal of Arrhythmia, 2014, 30, 1-28.	1.2	49
225	A missense mutation in the sodium channel $\hat{l}^2 lb$ subunit reveals SCN1B as a susceptibility gene underlying long QT syndrome. Heart Rhythm, 2014, 11, 1202-1209.	0.7	33
226	Atrial functional and geometrical remodeling in highly trained male athletes: for better or worse?. European Journal of Applied Physiology, 2014, 114, 1143-1152.	2.5	41
227	Left atrial size and function by three-dimensional echocardiography to predict arrhythmia recurrence after first and repeated ablation of atrial fibrillation. European Heart Journal Cardiovascular Imaging, 2014, 15, 515-522.	1.2	43
228	Transthoracic epicardial ablation of mitral isthmus for treatment of recurrent perimitral flutter. Heart Rhythm, 2014, 11, 26-33.	0.7	14
229	Use of MRI to guide electrophysiology procedures. Heart, 2014, 100, 1975-1984.	2.9	11
230	Rationale and Design of FIRE AND ICE: A Multicenter Randomized Trial Comparing Efficacy and Safety of Pulmonary Vein Isolation Using a Cryoballoon versus Radiofrequency Ablation with 3Dâ€Reconstruction. Journal of Cardiovascular Electrophysiology, 2014, 25, 1314-1320.	1.7	36
231	Mechanical Abnormalities Detected WithÂConventional Echocardiography AreÂAssociated With Response and Midterm Survival in CRT. JACC: Cardiovascular Imaging, 2014, 7, 969-979.	5.3	55
232	The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. European Heart Journal, 2014, 35, 1466-1478.	2.2	180
233	Myocardial motion and deformation patterns in an experimental swine model of acute LBBB/CRT and chronic infarct. International Journal of Cardiovascular Imaging, 2014, 30, 875-887.	1.5	12
234	Lung Function Abnormalities are Highly Frequent in Patients with Heart Failure and Preserved Ejection Fraction. Heart Lung and Circulation, 2014, 23, 273-279.	0.4	35

#	Article	IF	Citations
235	Atrial fibrosis in a chronic murine model of obstructive sleep apnea: mechanisms and prevention by mesenchymal stem cells. Respiratory Research, 2014, 15, 54.	3.6	44
236	Comments on the Usefulness of Echocardiography in Preparticipation Screening of Competitive Athletes. Response. Revista Espanola De Cardiologia (English Ed), 2014, 67, 782.	0.6	0
237	Short QT Syndrome: A Predictable Story. Cardiology, 2014, 128, 231-233.	1.4	18
238	Comentarios a la utilidad del ecocardiograma en la revisi \tilde{A}^3 n preparticipativa de deportistas de competici \tilde{A}^3 n. Respuesta. Revista Espanola De Cardiologia, 2014, 67, 782.	1.2	2
239	Integration of Mechanical, Structural and Electrical Imaging to Understand Response to Cardiac Resynchronization Therapy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 813-821.	0.6	2
240	Use of therapeutic hypothermia and extracorporeal life support after an unusual response to the ajmaline challenge in a patient with Brugada syndrome. Journal of Cardiology Cases, 2014, 10, 34-38.	0.5	11
241	Sinus rhythm detection of conducting channels and ventricular tachycardia isthmus in arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2014, 11, 747-754.	0.7	44
242	Integraci \tilde{A}^3 n de la imagen mec \tilde{A}_i nica, estructural y el \tilde{A} ©ctrica para entender la respuesta a la terapia de resincronizaci \tilde{A}^3 n cardiaca. Revista Espanola De Cardiologia, 2014, 67, 813-821.	1.2	6
243	The role of clinical, genetic and segregation evaluation in sudden infant death. Forensic Science International, 2014, 242, 9-15.	2.2	19
244	Risk Stratification and Treatment of Brugada Syndrome. Current Cardiology Reports, 2014, 16, 508.	2.9	16
245	Brugada syndrome and p.E61X_RANGRF. Cardiology Journal, 2014, 21, 121-127.	1.2	13
246	Ventricular Tachycardiac and Sudden Arrhythmic Death. , 2014, , 2971-2998.		0
247	Brugada Syndrome 1992–2012. , 2014, , 925-933.		1
248	The usefulness of the consensus clinical diagnostic criteria in Brugada syndrome. International Journal of Cardiology, 2013, 167, 2700-2704.	1.7	15
249	Development of a Swine Model of Left Bundle Branch Block for Experimental Studies of Cardiac Resynchronization Therapy. Journal of Cardiovascular Translational Research, 2013, 6, 616-622.	2.4	18
250	Role of novel DSP_p.Q986X genetic variation in arrhythmogenic right ventricular cardiomyopathy. European Journal of Medical Genetics, 2013, 56, 541-545.	1.3	3
251	The use of imaging for electrophysiological and devices procedures: a report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of Cardiovascular Imaging and the European Society of Cardiac Radiology, Europace, 2013, 15, 927-936.	1.7	38
252	Brugada syndrome 1992-2012: 20 years of scientific excitement, and more. European Heart Journal, 2013, 34, 3610-3615.	2.2	37

#	Article	IF	Citations
253	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex. New England Journal of Medicine, 2013, 369, 1395-1405.	27.0	688
254	Right bundle branch block: are we looking in the right direction?. European Heart Journal, 2013, 34, 86-88.	2.2	12
255	Effect of Cardiac Resynchronization Therapy on Left Ventricular Diastolic Function: Implications for Clinical Outcome. Journal of Cardiac Failure, 2013, 19, 795-801.	1.7	13
256	Consens per a la prevenci \tilde{A}^3 de la mort sobtada card \tilde{A} aca en els esportistes. Apunts Medicine De L'Esport, 2013, 48, 35-41.	0.5	12
257	Neurohormonal, Structural, and Functional Recovery Pattern After Premature Ventricular Complex Ablation Is Independent of Structural Heart Disease Status in Patients With Depressed LeftÂVentricular Ejection Fraction. Journal of the American College of Cardiology, 2013, 62, 1195-1202.	2.8	99
258	Cardiac autonomic control in Brugada syndrome patients during sleep: The effects of sleep disordered breathing. International Journal of Cardiology, 2013, 168, 3267-3272.	1.7	19
259	Analysis of the arrhythmogenic substrate in human heart failure. Cardiovascular Pathology, 2013, 22, 133-140.	1.6	8
260	Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 2013, 10, e85-e108.	0.7	159
261	Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation. International Journal of Cardiology, 2013, 168, 4093-4097.	1.7	57
262	Noncompaction Cardiomyopathy is Associated With Mechanical Dyssynchrony: A Potential Underlying Mechanism for Favorable Response to Cardiac Resynchronization Therapy. Journal of Cardiac Failure, 2013, 19, 80-86.	1.7	10
263	HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm, 2013, 10, 1932-1963.	0.7	1,587
264	A Missense Mutation in the Sodium Channel Î ² 2 Subunit Reveals <i>SCN2B</i> as a New Candidate Gene for Brugada Syndrome. Human Mutation, 2013, 34, 961-966.	2.5	96
265	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace, 2013, 15, 1389-1406.	1.7	494
266	Left Atrial Sphericity: A New Method to Assess Atrial Remodeling. Impact on the Outcome of Atrial Fibrillation Ablation. Journal of Cardiovascular Electrophysiology, 2013, 24, 752-759.	1.7	127
267	Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace, 2013, 15, 1337-1382.	1.7	281
268	Genetics of sudden cardiac death in children and young athletes. Cardiology in the Young, 2013, 23, 159-173.	0.8	24
269	Reuse of Pacemakers. Circulation, 2013, 127, 1177-1183.	1.6	34
270	Complete atrioventricular block does not reduce longâ€term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2013, 15, 1412-1418.	7.1	20

#	Article	IF	Citations
271	Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 877-884.	7.1	27
272	Genetics of arrhythmogenic right ventricular cardiomyopathy. Journal of Medical Genetics, 2013, 50, 280-289.	3.2	56
273	Three-Dimensional Architecture of Scar and Conducting Channels Based on High Resolution ce-CMR. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 528-537.	4.8	179
274	Losartan Prevents Heart Fibrosis Induced by Long-Term Intensive Exercise in an Animal Model. PLoS ONE, 2013, 8, e55427.	2.5	47
275	Manifold Learning Characterization of Abnormal Myocardial Motion Patterns: Application to CRT-Induced Changes. Lecture Notes in Computer Science, 2013, , 450-457.	1.3	1
276	Improving Safety of Epicardial Ventricular Tachycardia Ablation Using the Scar Dechanneling Technique and the Integration of Anatomy, Scar Components, and Coronary Arteries Into the Navigation System. Circulation, 2012, 125, e466-8.	1.6	15
277	Single-catheter radiofrequency ablation of a permanent junctional reciprocating tachycardia in a premature neonate. Cardiology in the Young, 2012, 22, 606-609.	0.8	11
278	Combined Endocardial and Epicardial Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia Incorporating Scar Dechanneling Technique. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 111-121.	4.8	189
279	Mapping Data Predictors of a Left Ventricular Outflow Tract Origin of Idiopathic Ventricular Tachycardia With V ₃ Transition and Septal Earliest Activation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 484-491.	4.8	28
280	The European CRT Survey: 1 year (9–15 months) followâ€up results. European Journal of Heart Failure, 2012, 14, 61-73.	7.1	87
281	Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response?. European Journal of Heart Failure, 2012, 14, 635-641.	7.1	33
282	Atrial Fibrillation Catheter Ablation Versus Surgical Ablation Treatment (FAST). Circulation, 2012, 125, 23-30.	1.6	357
283	ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace, 2012, 14, 1094-1103.	1.7	123
284	ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). Europace, 2012, 14, 278-293.	1.7	156
285	Psychosis, depression, and high risk for sudden cardiac death: time for co-operation between psychiatrists and cardiologists. European Heart Journal, 2012, 33, 687-688.	2.2	8
286	Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace, 2012, 14, 1578-1586.	1.7	71
287	Brugada Syndrome 2012. Circulation Journal, 2012, 76, 1563-1571.	1.6	161
288	Biventricular / Left Ventricular Pacing in Hypertrophic Obstructive Cardiomyopathy: An Overview. Indian Pacing and Electrophysiology Journal, 2012, 12, 114-123.	0.6	5

#	ARTICLE 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial	IF	CITATIONS
289	Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of	1.7	1,497
290	Cardiology (ESC) and the E. Europace, 2012, 14, 528-606. Improved Outcomes and Complications of Atrial Fibrillation Catheter Ablation Over Time: Learning Curve, Techniques, and Methodology. Revista Espanola De Cardiologia (English Ed.), 2012, 65, 131-138.	0.6	11
291	Anticoagulation Therapy in Patients With Heart Failure Due to Systolic Dysfunction and Sinus Rhythm: Analysis of REDINSCOR Registry. Revista Espanola De Cardiologia (English Ed), 2012, 65, 705-712.	0.6	4
292	Atlas-Based Quantification of Myocardial Motion Abnormalities: Added-Value for Understanding the Effect of Cardiac Resynchronization Therapy. Ultrasound in Medicine and Biology, 2012, 38, 2186-2197.	1.5	8
293	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Heart Rhythm, 2012, 9, 632-696.e21.	0.7	1,541
294	Displacement of the target ablation site and ventricles during premature ventricular contractions: Relevance for radiofrequency catheter ablation. Heart Rhythm, 2012, 9, 1050-1057.	0.7	16
295	Tratamiento anticoagulante en pacientes con insuficiencia cardiaca por disfunci \tilde{A}^3 n sist \tilde{A}^3 lica y ritmo sinusal: an \tilde{A}_1 lisis del registro REDINSCOR. Revista Espanola De Cardiologia, 2012, 65, 705-712.	1.2	10
296	Atrial fibrillation and atrial flutter in athletes. British Journal of Sports Medicine, 2012, 46, i37-i43.	6.7	72
297	Evolución de la mejora en los resultados y las complicaciones de la ablación por catéter de la fibrilación auricular: aprendizaje, técnicas y metodologÃa. Revista Espanola De Cardiologia, 2012, 65, 131-138.	1.2	28
298	Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. Journal of Electrocardiology, 2012, 45, 433-442.	0.9	335
299	Remodelado auricular adverso en atletas de alto rendimiento: Estudio de deformaci $ ilde{A}^3$ n auricular con speckle tracking 2D. Revista Chilena De Cardiolog $ ilde{A}$ 8, 2012, 31, 176-183.	0.0	0
300	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Journal of Interventional Cardiac Electrophysiology, 2012, 33, 171-257.	1.3	1,167
301	ISHNE/EHRA Expert Consensus on Remote Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs). Annals of Noninvasive Electrocardiology, 2012, 17, 36-56.	1.1	30
302	Temporal diffeomorphic free-form deformation: Application to motion and strain estimation from 3D echocardiography. Medical Image Analysis, 2012, 16, 427-450.	11.6	123
303	Increased Expression of Fatty-Acid and Calcium Metabolism Genes in Failing Human Heart. PLoS ONE, 2012, 7, e37505.	2.5	46
304	Cardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Training. Circulation, 2011, 123, 13-22.	1.6	394
305	Electrophysiologic testing predicts events in Brugada syndrome patients. Heart Rhythm, 2011, 8, 1595-1597.	0.7	50
306	Reply to the Editor—Biventricular pacing in hypertrophic obstructive cardiomyopathy. Heart Rhythm, 2011, 8, e26.	0.7	0

#	Article	IF	CITATIONS
307	Biventricular pacing in hypertrophic obstructive cardiomyopathy: A pilot study. Heart Rhythm, 2011, 8, 221-227.	0.7	34
308	Characteristics of inverse-computed epicardial electrograms of Brugada syndrome patients., 2011, 2011, 235-8.		2
309	Rebuttal to EP testing does not predict cardiac events in patients with Brugada syndrome. Heart Rhythm, 2011, 8, 1796.	0.7	4
310	DetecciÃ ³ n de un sÃndrome de Brugada en un reconocimiento médico laboral. Medicina Y Seguridad Del Trabajo, 2011, 57, 265-269.	0.1	1
311	Bifocal Right Ventricular Resynchronization for the Failing Right Ventricle. PACE - Pacing and Clinical Electrophysiology, 2011, 34, e78-81.	1.2	2
312	Comparison of Hemodynamic versus Dyssynchrony Assessment for Interventricular Delay Optimization with Echocardiography in Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 984-990.	1.2	9
313	Transient ST Elevation After Ketamine Intoxication: A New Cause of Acquired Brugada ECG Pattern. Journal of Cardiovascular Electrophysiology, 2011, 22, 91-94.	1.7	22
314	Electrocardiographic versus Echocardiographic Optimization of the Interventricular Pacing Delay in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2011, 22, 1129-1134.	1.7	48
315	Sleep-Disordered Breathing in Patients With the Brugada Syndrome. American Journal of Cardiology, 2011, 107, 709-713.	1.6	23
316	Effect of Repeated Radiofrequency Catheter Ablation on Left Atrial Function for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2011, 108, 1741-1746.	1.6	27
317	Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. Circulation, 2011, 123, 131-136.	1.6	446
318	Epicardial Ablation for Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 653-659.	4.8	210
319	Response to Letters Regarding Article, "Cardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Training― Circulation, 2011, 124, .	1.6	O
320	Integration of 3D Electroanatomic Maps and Magnetic Resonance Scar Characterization Into the Navigation System to Guide Ventricular Tachycardia Ablation. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 674-683.	4.8	153
321	State of the Art in Forensic Investigation of Sudden Cardiac Death. American Journal of Forensic Medicine and Pathology, 2011, 32, 1-16.	0.8	69
322	Diagnosis, management, and outcomes of patients with syncope and bundle branch block. European Heart Journal, 2011, 32, 1535-1541.	2.2	115
323	CardioPulse Articles. European Heart Journal, 2011, 32, 1173-1181.	2.2	5
324	The value of a family history of sudden death in patients with diagnostic type I Brugada ECG pattern. European Heart Journal, 2011, 32, 2153-2160.	2.2	81

#	Article	IF	CITATIONS
325	Entrapment of the circular mapping catheter in the mitral valve in two patients undergoing atrial fibrillation ablation. Europace, 2011, 13, 132-133.	1.7	16
326	Healthcare personnel resource burden related to in-clinic follow-up of cardiovascular implantable electronic devices: a European Heart Rhythm Association and Eucomed joint survey. Europace, 2011, 13, 1166-1173.	1.7	33
327	Determinants of geographic variations in implantation of cardiac defibrillators in the European Society of Cardiology member countries-data from the European Heart Rhythm Association White Book. Europace, 2011, 13, 654-662.	1.7	28
328	Barriers to implementation of evidence-based electrical therapies and the need for outcome research: role of European registries. Europace, 2011, 13, ii18-ii20.	1.7	24
329	The Brugada Syndrome. , 2011, , 165-187.		1
330	ICD Therapy in Channelopathies. , 2011, , 383-392.		0
331	An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace, 2010, 12, 626-633.	1.7	110
332	Decreased likelihood of response to cardiac resynchronization in patients with severe heart failure. European Journal of Heart Failure, 2010, 12, 283-287.	7.1	44
333	Response to "Resolution of Dyssynchronous Left Ventricular Failure via Cardiac Resynchronization and Subsequent Radiofrequency Ablation in an Infant with Preexcitation― Pediatric Cardiology, 2010, 31, 1257-1257.	1.3	2
334	Angiographic and Magnetic Resonance Imaging Evaluation of In-Hospital Delay in Primary Percutaneous Intervention Delivery on Myocardial Salvage. American Journal of Cardiology, 2010, 106, 924-930.	1.6	10
335	Analysis of mRNA from human heart tissue and putative applications in forensic molecular pathology. Forensic Science International, 2010, 203, 99-105.	2.2	38
336	Venice Chart International Consensus Document on Ventricular Tachycardia/Ventricular Fibrillation Ablation. Journal of Cardiovascular Electrophysiology, 2010, 21, 339-379.	1.7	97
337	The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2010, 21, 946-958.	1.7	25
338	Conduction abnormalities in the right ventricular outflow tract in Brugada syndrome detected body surface potential mapping., 2010, 2010, 2537-40.		6
339	Happy birthday European Heart Journal: in 30 years, from Cinderella to centre stage. European Heart Journal, 2010, 31, 1945-1950.	2.2	14
340	Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace, 2010, 12, 1084-1089.	1.7	138
341	Restoration of sinus rhythm in patients undergoing surgery for rheumatic valvular heart disease: is it worth the effort?. European Heart Journal, 2010, 31, 2572-2574.	2.2	4
342	Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace, 2010, 12, 24-29.	1.7	73

#	Article	IF	CITATIONS
343	Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace, 2010, 12, 30-36.	1.7	109
344	Tracing the European course of cardiac resynchronization therapy from 2006 to 2008. Europace, 2010, 12, 692-701.	1.7	39
345	Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace, 2010, 12, 1136-1140.	1.7	31
346	Defibrillation threshold decrease with the supradiaphragmatic extracardiac implantable cardioverter-defibrillator implantation technique. Europace, 2010, 12, 1649-1651.	1.7	1
347	Number of electrocardiogram leads displaying the diagnostic coved-type pattern in Brugada syndrome: a diagnostic consensus criterion to be revised. European Heart Journal, 2010, 31, 1357-1364.	2.2	68
348	Plasma tissue inhibitor of matrix metalloproteinaseâ€1 (TIMPâ€1): an independent predictor of poor response to cardiac resynchronization therapy. European Journal of Heart Failure, 2010, 12, 492-498.	7.1	16
349	Circumferential pulmonary vein ablation: Does use of a circular mapping catheter improve results? A prospective randomized study. Heart Rhythm, 2010, 7, 612-618.	0.7	29
350	Genetic Basis of Ventricular Arrhythmias. Heart Failure Clinics, 2010, 6, 249-266.	2.1	7
351	Brugada Syndrome 2010. Cardiac Electrophysiology Clinics, 2010, 2, 533-549.	1.7	2
352	KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. Heart Rhythm, 2010, 7, 199-205.	0.7	26
353	An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm, 2010, 7, 33-46.	0.7	649
354	Effects of Adipose Tissue-Derived Stem Cell Therapy After Myocardial Infarction: Impact of the Route of Administration. Journal of Cardiac Failure, 2010, 16, 357-366.	1.7	77
355	Arrhythmia and Right Heart Disease: From Genetic Basis to Clinical Practice. Revista Espanola De Cardiologia (English Ed), 2010, 63, 963-983.	0.6	12
356	R-wave peak time at DII: A new criterion for differentiating between wide complex QRS tachycardias. Heart Rhythm, 2010, 7, 922-926.	0.7	112
357	Respuesta. Revista Espanola De Cardiologia, 2010, 63, 620.	1.2	2
358	Arritmias y enfermedades del corazón derecho: de las bases genéticas a la clÃnica. Revista Espanola De Cardiologia, 2010, 63, 963-983.	1.2	29
359	Assessment of a novel device-based diagnostic algorithm to monitor patient status in moderate-to-severe heart failure: rationale and design of the CLEPSYDRA study. European Journal of Heart Failure, 2010, 12, 1363-1371.	7.1	9
360	Analysis of temporal delay in myocardial deformation throughout the cardiac cycle: Utility for selecting candidates for cardiac resynchronization therapy. Heart Rhythm, 2010, 7, 1580-1586.	0.7	6

#	Article	IF	CITATIONS
361	Temporal Diffeomorphic Free-Form Deformation for Strain Quantification in 3D-US Images. Lecture Notes in Computer Science, 2010, 13 , 1 -8.	1.3	16
362	Brugada Syndrome. , 2010, , 131-148.		0
363	Atlas-Based Quantification of Myocardial Motion Abnormalities: Added-value for the Understanding of CRT Outcome?. Lecture Notes in Computer Science, 2010, , 65-74.	1.3	0
364	The Brugada syndrome. Acta Cardiologica, 2009, 64, 795-801.	0.9	10
365	Six-minute walking test predicts long-term cardiac death in patients who received cardiac resynchronization therapy. Europace, 2009, 11, 338-342.	1.7	30
366	Left Atrial Posterior Wall Isolation Does Not Improve the Outcome of Circumferential Pulmonary Vein Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 35-40.	4.8	129
367	Letter by Mont et al Regarding Article, "Physical Activity and Incidence of Atrial Fibrillation in Older Adults: The Cardiovascular Health Study― Circulation, 2009, 119, e195; author reply e196.	1.6	3
368	Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. European Heart Journal, 2009, 30, 1880-1884.	2.2	104
369	The European cardiac resynchronization therapy survey. European Heart Journal, 2009, 30, 2450-2460.	2.2	215
370	Morphology discrimination criterion wavelet improves rhythm discrimination in single-chamber implantable cardioverter-defibrillators: Spanish Register of morphology discrimination criterion wavelet (REMEDIO). Europace, 2009, 11, 727-733.	1.7	26
371	Inappropriate shocks or inappropriate programming? A review of Guidant'sTM reconfirmation algorithm. Europace, 2009, 11, 1120-1122.	1.7	5
372	Electrophysiology: it is time to simplify!. Europace, 2009, 11, 985-986.	1.7	5
373	Midterm 'super-response' to cardiac resynchronization therapy by biventricular pacing with fusion: insights from electro-anatomical mapping. Europace, 2009, 11, 1675-1682.	1.7	47
374	Noninvasive Evaluation of Radiofrequency Lesions in the Human Ventricular Myocardium by Contrast-Enhanced Cardiac Magnetic Resonance. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 208-211.	4.8	7
375	Inferior and Lateral Electrocardiographic Repolarization Abnormalities in Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 154-161.	4.8	151
376	Mechanism of Decrease in Mitral Regurgitation After Cardiac Resynchronization Therapy. Circulation: Cardiovascular Imaging, 2009, 2, 444-450.	2.6	68
377	Electrocardiographic Optimization of Cardiac Resynchronization Devices: Simple, but Not So Simple!. American Journal of Cardiology, 2009, 103, 894.	1.6	2
378	Early Risk Stratification of Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction Who Undergo Percutaneous Coronary Intervention. American Journal of Cardiology, 2009, 103, 1073-1077.	1.6	25

#	Article	IF	CITATIONS
379	Long-Term Effect of Cardiac Resynchronization Therapy on Functional Mitral Valve Regurgitation. American Journal of Cardiology, 2009, 104, 383-388.	1.6	54
380	Relation of Plasma Brain Natriuretic Peptide Levels on Admission for ST-Elevation Myocardial Infarction to Left Ventricular End-Diastolic Volume Six Months Later Measured by Both Echocardiography and Cardiac Magnetic Resonance. American Journal of Cardiology, 2009, 104, 878-882.	1.6	29
381	Optimization of the Interventricular Delay in Cardiac Resynchronization Therapy Using the QRS Width. American Journal of Cardiology, 2009, 104, 1407-1412.	1.6	39
382	When Our Best Is Not Enough: The Death of a Teenager with Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 2009, 20, 108-109.	1.7	12
383	Variability of the Diagnostic ECG Pattern in an ICD Patient Population with Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 2009, 20, 69-75.	1.7	74
384	Genetic Modulation of Brugada Syndrome by a Common Polymorphism. Journal of Cardiovascular Electrophysiology, 2009, 20, 1137-1141.	1.7	70
385	Reexcitation mechanisms in epicardial tissue: Role of Ito density heterogeneities and INa inactivation kinetics. Journal of Theoretical Biology, 2009, 259, 850-859.	1.7	16
386	Assessment of Mitral Valve Anatomy and Geometry With Multislice Computed Tomography. JACC: Cardiovascular Imaging, 2009, 2, 556-565.	5 . 3	142
387	The Genetic Basis of Malignant Arrhythmias and Cardiomyopathies. Revista Espanola De Cardiologia (English Ed), 2009, 62, 422-436.	0.6	1
388	Brugada Syndrome. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1297-1315.	0.6	40
389	Drugs and Brugada syndrome patients: Review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm, 2009, 6, 1335-1341.	0.7	342
390	Bases genéticas de las arritmias malignas y las miocardiopatÃas. Revista Espanola De Cardiologia, 2009, 62, 422-436.	1.2	5
391	SÃndrome de Brugada. Revista Espanola De Cardiologia, 2009, 62, 1297-1315.	1.2	89
392	Betablockers: Is the Reduction of Sudden Death Related to Pure Electrophysiologic Effects?. Cardiovascular Drugs and Therapy, 2008, 22, 163-164.	2.6	0
393	Application of a Clinical Magnet over Implantable Cardioverter Defibrillators: Is It Safe and Useful?. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1641-1645.	1.2	10
394	Left Atrial Contractility is Preserved After Successful Circumferential Pulmonary Vein Ablation in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2008, 19, 374-379.	1.7	47
395	Response to the Editor:. Journal of Cardiovascular Electrophysiology, 2008, 19, E50.	1.7	0
396	Differences in 12â€Lead Electrocardiogram Between Symptomatic and Asymptomatic Brugada Syndrome Patients. Journal of Cardiovascular Electrophysiology, 2008, 19, 380-383.	1.7	101

#	ARTICLE	IF	Citations
397	Fate of Left Atrial Function as Determined by Real-Time Three-Dimensional Echocardiography Study After Radiofrequency Catheter Ablation for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2008, 101, 1285-1290.	1.6	58
398	Comparison of Benefits and Mortality in Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation Versus Patients in Sinus Rhythm (Results of the Spanish Atrial Fibrillation and) Tj ETQq0 0 0 rgBT /C	verlaick 10	Tf 5 6 0697 Td
399	Brugada Syndrome. Progress in Cardiovascular Diseases, 2008, 51, 1-22.	3.1	113
400	Gender Differences in Clinical Manifestations of Brugada Syndrome. Journal of the American College of Cardiology, 2008, 52, 1567-1573.	2.8	265
401	HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): Description of Techniques, Indications, Personnel, Frequency and Ethical Considerations. Heart Rhythm, 2008, 5, 907-925 HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices	0.7	279
402	Developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure	1.7	215
403	Association of ESC (HFA), and the Heart Fail. Europace, 2008, 10, 707-725. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. Heart Rhythm, 2008, 5, 1434-1440.	0.7	93
404	Genetic Basis of Ventricular Arrhythmias. Cardiology Clinics, 2008, 26, 335-353.	2.2	20
405	Clinical Heterogeneity in Sodium Channelopathies. Cardiology, 2008, 110, 116-122.	1.4	9
406	Response to Letter Regarding Article, "Induced Brugada-Type Electrocardiogram, a Sign for Imminent Malignant Arrhythmias― Circulation, 2008, 118, .	1.6	0
407	Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace, 2008, 10, 15-20.	1.7	237
408	Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. Europace, 2008, 10, 336-346.	1.7	221
409	Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace, 2008, 10, 618-623.	1.7	289
410	Cooled-tip vs. 8 mm-tip catheter for circumferential pulmonary vein ablation: comparison of efficacy, safety, and lesion extension. Europace, 2008, 10, 955-960.	1.7	18
411	Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter. Europace, 2008, 11, 11-17.	1.7	224
412	Induced Brugada-Type Electrocardiogram, a Sign for Imminent Malignant Arrhythmias. Circulation, 2008, 117, 1890-1893.	1.6	163
413	The European Heart Journal goes global: the road ahead of the editorial team 2009-2011. European Heart Journal, 2008, 30, 1-5. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation:	2.2	21
414	Recommendations for Personnel, Policy, Procedures and Follow-Up: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Soci. Europace, 2007, 9, 335-379.	1.7	741

#	Article	IF	CITATIONS
415	Cardiac resynchronization therapy: predictive factors of unsuccessful left ventricular lead implant. European Heart Journal, 2007, 28, 450-456.	2.2	24
416	Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. European Heart Journal, 2007, 28, 836-841.	2.2	351
417	Is there an anatomical substrate for idiopathic paroxysmal atrial fibrillation? A case–control echocardiographic study. Europace, 2007, 9, 294-298.	1.7	27
418	Characterization of focal right atrial appendage tachycardia. Europace, 2007, 10, 105-109.	1.7	40
419	Predictors of arrhythmia recurrence in patients with lone atrial fibrillation. Europace, 2007, 10, 9-14.	1.7	23
420	Optimizing the clinical use of implantable defibrillators in patients with Brugada syndrome. Country Review Ukraine, 2007, 9, 174-180.	0.8	13
421	Lone atrial fibrillation and sport practice. The no gain without pain history revisited again?. International Journal of Cardiology, 2007, 118, 414-415.	1.7	6
422	Corrigendum to "Sport practice and the risk of lone atrial fibrillation: A case–control study― [International Journal of Cardiology 108/3 (2006) 332–337]. International Journal of Cardiology, 2007, 123, 74.	1.7	2
423	HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. Heart Rhythm, 2007, 4, 816-861.	0.7	1,258
424	Low Exposure Radiation with Conventional Guided Radiofrequency Catheter Ablation in Pregnant Women. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1299-1302.	1.2	29
425	Electrocardiographic Optimization of Interventricular Delay in Cardiac Resynchronization Therapy: A Simple Method to Optimize the Device. Journal of Cardiovascular Electrophysiology, 2007, 18, 1252-1257.	1.7	57
426	Usefulness of Ventricular Dyssynchrony Measured Using M-Mode Echocardiography to Predict Response to Resynchronization Therapy. American Journal of Cardiology, 2007, 100, 84-89.	1.6	29
427	Pseudo–Atrial Fibrillation, Rare Manifestation of Multiple Anterograde Atrioventricular Nodal Pathways. American Journal of Cardiology, 2007, 100, 154-156.	1.6	12
428	Optimizing the Programation of Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Left Bundle Branch Block. American Journal of Cardiology, 2007, 100, 1002-1006.	1.6	84
429	Channelopathies: a New Category of Diseases Causing Sudden Death. Herz, 2007, 32, 185-191.	1.1	41
430	Selective segmental ostial ablation and circumferential pulmonary veins ablation. Results of an individualized strategy to cure refractory atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2007, 19, 19-27.	1.3	6
431	Sport practice and the risk of lone atrial fibrillation: A case–control study. International Journal of Cardiology, 2006, 108, 332-337.	1.7	212
432	Transient endothelial dysfunction is present shortly after cardioversion in patients with lone atrial fibrillation. Thrombosis Research, 2006, 117, 235-240.	1.7	3

#	Article	IF	CITATIONS
433	Anodal Capture in Cardiac Resynchronization Therapy Implications for Device Programming. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 940-945.	1.2	34
434	Familial Pseudo-Wolff-Parkinson-White Syndrome. Journal of Cardiovascular Electrophysiology, 2006, 17, 724-732.	1.7	44
435	Response to the Editor:. Journal of Cardiovascular Electrophysiology, 2006, 17, E10-E10.	1.7	O
436	Relation of Response to Cardiac Resynchronization Therapy to Left Ventricular Reverse Remodeling. American Journal of Cardiology, 2006, 97, 876-881.	1.6	32
437	Electrocardiogram interpretation and class I blocker challenge in Brugada syndrome. Journal of Electrocardiology, 2006, 39, S115-S118.	0.9	23
438	European Heart Rhythm Association Guidance Document on cardiac rhythm management product performance. Europace, 2006, 8, 313-322.	1.7	20
439	Epicardial ablation of syncopal ventricular tachycardia. Utility of the electrocardiogram. Europace, 2006, 8, 338-340.	1.7	3
440	Compound Heterozygous Mutations P336L and I1660V in the Human Cardiac Sodium Channel Associated With the Brugada Syndrome. Circulation, 2006, 114, 2026-2033.	1.6	102
441	Recurrent syncope: an unusual presentation of Brugada syndrome. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 573-577.	3.3	10
442	Diphenhydramine Overdose and Brugada Sign. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 730-732.	1.2	41
443	Brugada syndrome: From cell to bedside. Current Problems in Cardiology, 2005, 30, 9-54.	2.4	105
444	Predictors of Lack of Response to Resynchronization Therapy. American Journal of Cardiology, 2005, 95, 1436-1440.	1.6	212
445	Incidence of Pulmonary Vein Stenosis in Patients Submitted to Atrial Fibrillation Ablation: A Comparison of the Selective Segmental Ostial Ablation vs the Circumferential Pulmonary Veins Ablation. Journal of Interventional Cardiac Electrophysiology, 2005, 14, 21-25.	1.3	40
446	Brugada Syndrome: Report of the Second Consensus Conference. Circulation, 2005, 111, 659-670.	1.6	1,639
447	Patients With an Asymptomatic Brugada Electrocardiogram Should Undergo Pharmacological and Electrophysiological Testing. Circulation, 2005, 112, 279-292.	1.6	201
448	De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovascular Research, 2005, 68, 433-440.	3.8	280
449	Electrocardiographic optimization of interventricular delay in cardiac resynchronization therapy: Correlation with echocardiography. Heart Rhythm, 2005, 2, S289.	0.7	1
450	Cryptic 5? splice site activation in SCN5A associated with Brugada syndrome. Journal of Molecular and Cellular Cardiology, 2005, 38, 555-560.	1.9	51

#	Article	IF	CITATIONS
451	Potential Proarrhythmic Effects of Biventricular Pacing. Journal of the American College of Cardiology, 2005, 46, 2340-2347.	2.8	122
452	Brugada Syndrome: Report of the Second Consensus Conference. Heart Rhythm, 2005, 2, 429-440.	0.7	429
453	The Brugada Syndrome. , 2005, , 697-703.		7
454	Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG. Circulation, 2004, 109, 30-35.	1.6	804
455	Electrocardiographic Recognition of the Epicardial Origin of Ventricular Tachycardias. Circulation, 2004, 109, 1842-1847.	1.6	335
456	Radiofrequency Catheter Ablation for Arrhythmic Storm in Patients with An Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 971-975.	1.2	57
457	Short Head-Up Tilt Test Potentiated with Oral Nitroglycerine:. Comparison with a Conventional Test Using Isoproterenol. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 1085-1088.	1.2	9
458	T Wave Oversensing by a Cardioverter Defibrillator Implanted in a Patient with the Brugada Syndrome. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 1563-1565.	1.2	23
459	Phenotypic Characterization of a Large European Family with Brugada Syndrome Displaying a Sudden Unexpected Death Syndrome Mutation inSCN5A:. Journal of Cardiovascular Electrophysiology, 2004, 15, 64-69.	1.7	50
460	Orthodromic Pacemaker-Mediated Tachycardia in a Biventricular System Without an Atrial Electrode. Journal of Cardiovascular Electrophysiology, 2004, 15, 1100-1102.	1.7	15
461	Value of Electrocardiographic Parameters and Ajmaline Test in the Diagnosis of Brugada Syndrome Caused by SCN5A Mutations. Circulation, 2004, 110, 3023-3027.	1.6	163
462	Value of the implantable loop recorder for the management of patients with unexplained syncope. Europace, 2004, 6, 70-76.	1.7	77
463	The Brugada Syndrome. , 2004, , 625-632.		4
464	Comparison of effectiveness of implantable cardioverter defibrillator in patients with idiopathic dilated cardiomyopathy versus those with proved coronary heart disease. American Journal of Cardiology, 2003, 92, 1227-1230.	1.6	3
465	Natural History of Brugada Syndrome:. Journal of Cardiovascular Electrophysiology, 2003, 14, 455-457.	1.7	192
466	Electrical Interference from an Abdominal Muscle Stimulator Unit on an Implantable Cardioverter Defibrillator:. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 1292-1293.	1.2	12
467	Reversibility of Cardiac Abnormalities in Adolescents With Anorexia Nervosa After Weight Recovery. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 808-813.	0.5	181
468	Brugada syndrome: 1992–2002. Journal of the American College of Cardiology, 2003, 41, 1665-1671.	2.8	176

#	Article	IF	CITATIONS
469	Nonsurgical transthoracic epicardial radiofrequency ablation. Journal of the American College of Cardiology, 2003, 41, 2036-2043.	2.8	135
470	Determinants of Sudden Cardiac Death in Individuals With the Electrocardiographic Pattern of Brugada Syndrome and No Previous Cardiac Arrest. Circulation, 2003, 108, 3092-3096.	1.6	509
471	Dronedarone for prevention of atrial fibrillation: A dose-ranging study. European Heart Journal, 2003, 24, 1481-1487.	2.2	295
472	Endurance athletes: exploring the limits andbeyond. European Heart Journal, 2003, 24, 1469-1470.	2.2	2
473	Ablación por radiofrecuencia para el tratamiento de la fibrilación auricular focal a través de cartografÃa circunferencial y aislamiento segmentario de las venas pulmonares. Revista Espanola De Cardiologia, 2003, 56, 361-367.	1.2	7
474	The Brugada Syndrome. Contemporary Cardiology, 2003, , 427-445.	0.1	0
475	Long-Term Follow-Up of Individuals With the Electrocardiographic Pattern of Right Bundle-Branch Block and ST-Segment Elevation in Precordial Leads V 1 to V 3. Circulation, 2002, 105, 73-78.	1.6	593
476	Proposed Diagnostic Criteria for the Brugada Syndrome. Circulation, 2002, 106, 2514-2519.	1.6	779
477	Polymorphic Reentrant Ventricular Tachycardia in the Isolated Rabbit Heart Studied by High-Density Mapping. Circulation, 2002, 105, 3053-3061.	1.6	30
478	Relevance of Atrial Fibrillation Classification in Clinical Practice. Journal of Cardiovascular Electrophysiology, 2002, 13, S27-30.	1.7	3
479	Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Human Molecular Genetics, 2002, 11, 337-345.	2.9	334
480	Novel mutations in domain I of SCN5A cause Brugada syndrome. Molecular Genetics and Metabolism, 2002, 75, 317-324.	1.1	61
481	Prolonged repolarization in long QT3 syndrome: unusual electrocardiographic findings. International Journal of Cardiology, 2002, 82, 71-73.	1.7	4
482	Fever Unmasking the Brugada Syndrome. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 1646-1648.	1.2	128
483	Radiofrequency Catheter Ablation of an Incessant Supraventricular Tachycardia in a Premature Neonate. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 866-868.	1.2	6
484	The syndrome of right bundle branch block, ST segment elevation in V1 to V3 and sudden death. Cardiovascular Drugs and Therapy, 2002, 16 , $25-27$.	2.6	10
485	ECG phenomenon of idiopathic and paradoxical short QT intervals. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 49-53.	1.0	54
486	The Brugada syndrome. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 45-48.	1.0	27

#	Article	IF	CITATIONS
487	Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome. Journal of the American College of Cardiology, 2001, 37, 529-533.	2.8	103
488	Asymptomatic Patients with a Brugada Electrocardiogram: Are They at Risk?. Journal of Cardiovascular Electrophysiology, 2001, 12, 7-8.	1.7	11
489	Prognostic Value of Electrophysiologic Investigations in Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 2001, 12, 1004-1007.	1.7	142
490	The Brugada syndrome. Cardiovascular Drugs and Therapy, 2001, 15, 15-17.	2.6	3
491	Outcomes after radiofrequency catheter ablation of atrial tachycardia. American Journal of Cardiology, 2001, 87, 886-890.	1.6	60
492	Idiopathic Short QT Interval:A New Clinical Syndrome?. Cardiology, 2000, 94, 99-102.	1.4	584
493	Spontaneous Recurrent Ventricular Fibrillation in a Patient with a Structurally Normal Heart. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 266-267.	1.2	3
494	Arrhythmia Induction by Antiarrhythmic Drugs. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 291-292.	1.2	62
495	The Brugada Syndrome. Annals of Noninvasive Electrocardiology, 2000, 5, 88-91.	1.1	5
496	Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. Journal of Electrocardiology, 2000, 33, 41-47.	0.9	102
497	Sudden death in high-risk family members: Brugada syndrome. American Journal of Cardiology, 2000, 86, K40-K43.	1.6	23
498	The Brugada syndrome. Current Cardiology Reports, 2000, 2, 507-514.	2.9	75
499	Sodium Channel Blockers Identify Risk for Sudden Death in Patients With ST-Segment Elevation and Right Bundle Branch Block but Structurally Normal Hearts. Circulation, 2000, 101, 510-515.	1.6	767
500	Brugada Syndrome Genetics. Developments in Cardiovascular Medicine, 2000, , 147-180.	0.1	0
501	Dispersion-based reentry: mechanism of initiation of ventricular tachycardia in isolated rabbit hearts. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H413-H423.	3.2	35
502	Ionic Mechanisms Responsible for the Electrocardiographic Phenotype of the Brugada Syndrome Are Temperature Dependent. Circulation Research, 1999, 85, 803-809.	4.5	557
503	The Brugada Syndrome. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 202-204.	1.0	2
504	Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. American Journal of Cardiology, 1999, 83, 98-100.	1.6	95

#	Article	IF	Citations
505	Arrhythmia recurrence in patients with a healed myocardial infarction who received an implantable defibrillator: analysis according to the clinical presentation. Journal of the American College of Cardiology, 1999, 34, 351-357.	2.8	23
506	Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature, 1998, 392, 293-296.	27.8	1,734
507	Long-Term Follow-Up in Patients with the Permanent Form of Junctional Reciprocating Tachycardia Treated with Radiofrequency Ablation. PACE - Pacing and Clinical Electrophysiology, 1998, 21, 2073-2078.	1.2	56
508	Enhanced Detection Criteria in Implantable Defibrillators. Journal of Cardiovascular Electrophysiology, 1998, 9, 261-268.	1.7	112
509	Hypertrophic Cardiomyopathy: Role of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 1998, 31, 1081-1085.	2.8	63
510	Right Bundle-Branch Block and ST-Segment Elevation in Leads V $<$ sub $>$ 1 $<$ /sub $>$ Through V $<$ sub $>$ 3 $<$ /sub $>$. Circulation, 1998, 97, 457-460.	1.6	696
511	Identification of a Genetic Locus for Familial Atrial Fibrillation. New England Journal of Medicine, 1997, 336, 905-911.	27.0	533
512	Hemodynamic Deterioration Following Radiofrequency Ablation of the Atrioventricular Conduction System. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2422-2428.	1.2	93
513	Ventricular Fibrillation and Sudden Death After Radiofrequency Catheter Ablation of the Atrioventricular Junction. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 343-348.	1.2	153
514	Radiofrequency Ablation of Concealed Left Free-Wall Accessory Pathways Without Coronary Sinus Catheterization: Journal of Cardiovascular Electrophysiology, 1997, 8, 249-253.	1.7	10
515	Further Characterization of the Syndrome of Right Bundle Branch Block, ST Segment Elevation, and Sudden Cardiac Death. Journal of Cardiovascular Electrophysiology, 1997, 8, 325-331.	1.7	236
516	Atrial Fibrillation Induced by Atrioventricular Nodal Reentrant Tachycardia. American Journal of Cardiology, 1997, 79, 681-682.	1.6	46
517	What to Do in Patients with No Structural Heart Disease and Sudden Arrhythmic Death?. American Journal of Cardiology, 1996, 78, 69-75.	1.6	52
518	A Fast and Reliable Algorithm to Localize Accessory Pathways Based on the Polarity of the QRS Complex on the Surface ECG During Sinus Rhythm. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 1615-1627.	1.2	76
519	The Differential Diagnosis of a Regular Tachycardia with a Wide QRS Complex on the 12-Lead ECG: Ventricular Tachycardia, Supraventricular Tachycardia with Aberrant Intraventricular Conduction, and Supraventricular Tachycardia with Anterograde Conduction Over an Accessory Pathway. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 1515-1524.	1.2	69
520	Epicardial and subselective transcoronary chemical ablation of incessant ventricular tachycardia. Catheterization and Cardiovascular Diagnosis, 1993, 28, 323-327.	0.3	12
521	The Complexity of Mechanisms in Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 680-686.	1.2	9
522	Value of clinical variables for risk stratification in patients with sustained ventricular tachycardia and history of myocardial infarction. American Journal of Cardiology, 1993, 72, 349-351.	1.6	4

#	Article	IF	CITATIONS
523	Investigation of palpitations. Lancet, The, 1993, 341, 1254-1258.	13.7	52
524	The Hemodynamic Mechanism of Pounding in the Neck in Atrioventricular Nodal Reentrant Tachycardia. New England Journal of Medicine, 1992, 327, 772-774.	27.0	72
525	Electrophysiologic and Arrhythmogenic Effects of Bupivacaine. Anesthesiology, 1992, 77, 132-141.	2.5	77
526	Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. Journal of the American College of Cardiology, 1992, 20, 1391-1396.	2.8	3,069
527	The electrocardiographic, clinical, and electrophysiologic spectrum of idiopathic monomorphic ventricular tachycardia. American Heart Journal, 1992, 124, 746-753.	2.7	50
528	Longitudinal dissociation of atrioventricular accessory pathways. Journal of the American College of Cardiology, 1991, 17, 161-166.	2.8	36
529	Clinical and electrophysiologic characteristics of exercise-related idiopathic ventricular tachycardia. American Journal of Cardiology, 1991, 68, 897-900.	1.6	68
530	Clinical and electrophysiologic characteristics of patients with antidromic circus movement tachycardia in the Wolff-Parkinson-White syndrome. American Journal of Cardiology, 1990, 66, 1082-1091.	1.6	50
531	Mechanism of action of sotalol in supraventricular arrhythmias. Cardiovascular Drugs and Therapy, 1990, 4, 619-623.	2.6	7
532	Electrocardiogram of Brugada Syndrome and Its Dynamic Patterns., 0,, 417-424.		2
533	Prognosis in Individuals with Brugada Syndrome. , 0, , 184-193.		0
534	Atrial Tachyarrhythmias in Brugada Syndrome. , 0, , 178-183.		1
535	Treatment of Brugada Syndrome with an Implantable Cardioverter Defibrillator. , 0, , 194-201.		2
536	Pharmacologic Approach to Therapy of Brugada Syndrome: Quinidine as an Alternative to ICD Therapy?. , 0, , 202-211.		3
537	Potential for Ablation Therapy in Patients with Brugada Syndrome. , 0, , 212-220.		О
538	Value of 12 Lead Electrocardiogram and Derived Methodologies in the Diagnosis of Brugada Disease. , 0, , 87-110.		4
539	ST Segment Elevation and Sudden Death in the Athlete. , 0, , 119-129.		7
540	Brugada Syndrome: Role of Genetics in Clinical Practice. , 0, , 130-139.		1

#	Article	IF	CITATIONS
541	Gender Differences in Brugada Syndrome. , 0, , 149-156.		O
542	Predisposing Factors., 0,, 157-165.		1
543	Acquired Forms of Brugada Syndrome. , 0, , 166-177.		13
544	Biophysical Analysis of Mutant Sodium Channels in Brugada Syndrome. , 0, , 26-41.		2
545	Brugada Syndrome: Relationship to other Arrhythmogenic Syndromes. , 0, , 111-118.		1
546	Cellular Mechanisms Underlying the Brugada Syndrome. , 0, , 52-77.		8
547	History of the Brugada Syndrome. , 0, , 23-25.		1
548	Brugada Syndrome: Overview. , 0, , 1-22.		0
549	Genotype–Phenotype Relationship in the Brugada Syndrome. , 0, , 140-148.		0
550	Molecular Genetics of the Brugada Syndrome. , 0, , 42-51.		3
551	Brugada Syndrome: Diagnostic Criteria. , 0, , 78-86.		0
552	Negative Autopsy in Infant and Juvenile Population: Role of Cardiac Arrhythmias. , 0, , .		0
553	The Brugada Syndrome. , 0, , 427-446.		5
554	Update on Genes Associated with Arrhythmogenic Cardiomyopathy. , 0, , .		1